Ribociclib Succinate

CAS 1374639-75-4

General Information

Ribociclib succinate is a type of cyclin-dependent kinase inhibitor. It was developed by Novartis and Astex Pharmaceuticals. It is used to treat hormone-receptor positive (HR+), HER2 negative (HER2-) breast cancer that is advanced or has spread to other parts of the body.

About the API

Systematic name 7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide succinate
Trade name(s) Kisqali
Technology Synthetic
Molecular Formula C27H36N8O5
Therapeutic category Oncology
Available formulations Oral Solid
Regulations US DMF Flag US DMF